Sort
85,873 grants matching “alzheimers”
Modulatory Role of Blood-Brain-Barrier and Enzymatic Activity in an Innovative Human Model of Anticholinergic Drug Induced Dementia
$1,500,000James J Hickman · Hesperos, Llc · R44 · FY2025 · AG
DOMINANTLY INHERITED ALZHEIMER NETWORK TRIAL: AN OPPORTUNITY TO PREVENT DEMENTIA
$1,500,000Randall J Bateman · Washington University · U01 · FY2014 · AG
DOMINANTLY INHERITED ALZHEIMER NETWORK TRIAL: AN OPPORTUNITY TO PREVENT DEMENTIA
$1,500,000Randall J Bateman · Washington University · U01 · FY2013 · AG
IND, FIH study and 3-month tox for PTI-125, a novel therapeutic for Alzheimer's disease
$1,500,000Lindsay H Burns · Cassava Sciences, Inc · R44 · FY2017 · AG
The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD
$1,500,000Eric Leven Eric Leven Eric Leven · Rip Road, Inc. · R42 · FY2023 · AG
Enabling nationwide AD PET imaging to support most efficient clinical trials by adoption of radically simplified and standardized quality control in commercial production of AD PET tracers.
$1,499,998Arkadij Elizarov · Trace-Ability, Inc. · R44 · FY2025 · AG
Developing an Intraoperative EEG-Guided Precision Anesthesia Management System to Prevent Postoperative Delirium in Elderly and Patients at Risk for Alzheimer's & Related Dementias
$1,499,986Tuan Le Mau · Pascall Systems, Incorporated · R44 · FY2025 · AG
Emory Alzheimer's Disease Center
$1,499,974Allan I Levey · Emory University · P50 · FY2014 · AG
Preclinical Efficacy and Safety Evaluation of Oral AST-004 for Moderate Traumatic Brain Injury (TBI)
$1,499,886Theodore E Liston · Astrocyte Pharmaceuticals, Inc. · R44 · FY2025 · NS
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.
$1,499,874Manfred Windisch · Pharmatrophix, Inc. · R01 · FY2016 · AG
Neuropathology of CTE and Delayed Effects of TBI: Toward In-Vivo Diagnostics
$1,499,710Wayne A Gordon · Icahn School Of Medicine At Mount Sinai · U01 · FY2016 · NS
A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.
$1,499,544Manfred Windisch · Pharmatrophix, Inc. · R01 · FY2017 · AG
PRIORITY-SETTING FOR PREVENTION AND TREATMENT-RELATED RESEARCH ON ALZHEIMER'S DISEASE AND RELATED DEMENTIAS AT THE NIH
$1,499,309Robert Day · National Academy Of Sciences · N01 · FY2023 · OD
Collaborative Research: ABI Innovation: Interpretable Machine Learning to Identify Molecular Markers for Complex Phenotypes
$1,499,266Su-In Lee · University Of Washington · · FY2018 · BIO
EXCITATORY TRANSMITTERS, MEMORY, AGING AND DEMENTIA
$1,499,255Washington University · P01 · FY2004 · AG
A National Resource for Postmortem Brain Research
$1,498,782Francine M. Benes · Mclean Hospital · R24 · FY2010 · MH
The Mexican Health Aging Study (MHAS)
$1,498,467Rebeca Wong · University Of Texas Med Br Galveston · R01 · FY2023 · AG
Are there ethnic differences in brain amyloid and tau in the seventh decade of life?
$1,497,958Jose A Luchsinger · Columbia University Health Sciences · R01 · FY2018 · AG
GMP Production of a Tau Oligomer Inhibitor to Enable Clinical Development forADRD
$1,497,873James G. Moe · Oligomerix, Inc · R44 · FY2024 · AG
The Microvascular Aging Effects - Women's Evaluation of Systemic aging Tenacity in Heart, Brain and Frailty (MAE-WEST HBF) ("You are never too old to become younger!")
$1,497,502C. Noel Bairey Merz · Cedars-Sinai Medical Center · U54 · FY2025 · AG
CLINICAL OPERATIONS CORE
$1,497,340Paul S. Aisen · University Of California, San Diego · U19 · FY2019 · AG
Mechanisms of molecular machines that regulate the neuronal cytoskeleton
$1,497,271Antonina Roll-Mecak · National Institute Of Neurological Disorders And Stroke · ZIA · FY2015 · NS
Role of mid- and late-life risk factors in social inequalities in Alzheimer's Disease and Related Dementias
$1,497,105Archana Singh-Manoux · Inserm Paris 5 · RF1 · FY2019 · AG
Optimization and preclinical development of soluble gamma-secretase modulators for AD
$1,497,030Steven Lee Wagner · University Of California, San Diego · U01 · FY2018 · AG
ESTROGEN AND THE AGING BRAIN
$1,496,536John H Morrison · Icahn School Of Medicine At Mount Sinai · P01 · FY2009 · AG